The expected toxicity rate at the maximum tolerated dose in the standard phase I cancer clinical trial design

Seung Ho Kang, Chul Ahn

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

A main purpose of Phase I cancer clinical trials is to identify the maximum tolerated dose (MTD) of a new agent for experimentation in Phase II and III studies. The continual reassessment method has been shown to be superior to the standard design. However, in practice, the standard design has still been widely used. Therefore, it is important to investigate the performance of the standard design accurately. In this paper, we develop an algorithm to compute the exact distribution of the recommended dose level in the standard design. The algorithm is a better tool than simulation in the investigation of the operating characteristics of the standard design, because it does not involve any sampling error and computing time is much shorter than simulation. With the algorithm, the expected toxicity rate at the MTD in the standard design is investigated extensively for some dose-toxicity curves in a certain range.

Original languageEnglish (US)
Pages (from-to)1189-1199
Number of pages11
JournalDrug Information Journal
Volume35
Issue number4
StatePublished - 2001

Fingerprint

Clinical Trials, Phase I
Maximum Tolerated Dose
Toxicity
Neoplasms
Selection Bias
Sampling

Keywords

  • Cancer
  • Continual reassessment method
  • Dose finding studies
  • Toxicity

ASJC Scopus subject areas

  • Health Informatics
  • Public Health, Environmental and Occupational Health
  • Nursing(all)
  • Pharmacology

Cite this

The expected toxicity rate at the maximum tolerated dose in the standard phase I cancer clinical trial design. / Kang, Seung Ho; Ahn, Chul.

In: Drug Information Journal, Vol. 35, No. 4, 2001, p. 1189-1199.

Research output: Contribution to journalArticle

@article{8557daf5667e4960924b58b8bc4e43d8,
title = "The expected toxicity rate at the maximum tolerated dose in the standard phase I cancer clinical trial design",
abstract = "A main purpose of Phase I cancer clinical trials is to identify the maximum tolerated dose (MTD) of a new agent for experimentation in Phase II and III studies. The continual reassessment method has been shown to be superior to the standard design. However, in practice, the standard design has still been widely used. Therefore, it is important to investigate the performance of the standard design accurately. In this paper, we develop an algorithm to compute the exact distribution of the recommended dose level in the standard design. The algorithm is a better tool than simulation in the investigation of the operating characteristics of the standard design, because it does not involve any sampling error and computing time is much shorter than simulation. With the algorithm, the expected toxicity rate at the MTD in the standard design is investigated extensively for some dose-toxicity curves in a certain range.",
keywords = "Cancer, Continual reassessment method, Dose finding studies, Toxicity",
author = "Kang, {Seung Ho} and Chul Ahn",
year = "2001",
language = "English (US)",
volume = "35",
pages = "1189--1199",
journal = "Drug Information Journal",
issn = "0092-8615",
publisher = "Drug Information Association",
number = "4",

}

TY - JOUR

T1 - The expected toxicity rate at the maximum tolerated dose in the standard phase I cancer clinical trial design

AU - Kang, Seung Ho

AU - Ahn, Chul

PY - 2001

Y1 - 2001

N2 - A main purpose of Phase I cancer clinical trials is to identify the maximum tolerated dose (MTD) of a new agent for experimentation in Phase II and III studies. The continual reassessment method has been shown to be superior to the standard design. However, in practice, the standard design has still been widely used. Therefore, it is important to investigate the performance of the standard design accurately. In this paper, we develop an algorithm to compute the exact distribution of the recommended dose level in the standard design. The algorithm is a better tool than simulation in the investigation of the operating characteristics of the standard design, because it does not involve any sampling error and computing time is much shorter than simulation. With the algorithm, the expected toxicity rate at the MTD in the standard design is investigated extensively for some dose-toxicity curves in a certain range.

AB - A main purpose of Phase I cancer clinical trials is to identify the maximum tolerated dose (MTD) of a new agent for experimentation in Phase II and III studies. The continual reassessment method has been shown to be superior to the standard design. However, in practice, the standard design has still been widely used. Therefore, it is important to investigate the performance of the standard design accurately. In this paper, we develop an algorithm to compute the exact distribution of the recommended dose level in the standard design. The algorithm is a better tool than simulation in the investigation of the operating characteristics of the standard design, because it does not involve any sampling error and computing time is much shorter than simulation. With the algorithm, the expected toxicity rate at the MTD in the standard design is investigated extensively for some dose-toxicity curves in a certain range.

KW - Cancer

KW - Continual reassessment method

KW - Dose finding studies

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=0035739843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035739843&partnerID=8YFLogxK

M3 - Article

VL - 35

SP - 1189

EP - 1199

JO - Drug Information Journal

JF - Drug Information Journal

SN - 0092-8615

IS - 4

ER -